Key result
Hydrodynamics-based delivery of IL-22-Ig gene therapy effectively suppressed experimental autoimmune myocarditis in rats by decreasing inflammatory gene expression in noncardiomyocytic cells.
Why the study?
Does IL-22-Ig gene therapy ameliorate experimental autoimmune myocarditis in rats?
Does IL-22-Ig gene therapy ameliorate experimental autoimmune myocarditis in rats?
IL-22-Ig gene therapy suppresses experimental autoimmune myocarditis in rats, likely by reducing inflammatory gene expression in noncardiomyocytic cells.
Answers are grounded in this paper and cite their sources.
IL-22-Ig gene therapy merits further preclinical testing in myocarditis models; leaves open translation to human autoimmune disease.
IL-22 is one of several cytokines with limited homology to IL-10. However, the biological activities of IL-22 are mostly unknown. The purpose of this study was to evaluate the effect of IL-22 on rat experimental autoimmune myocarditis (EAM) and elucidate an aspect of the biological activities of IL-22. Rats were immunized on day 0; IL-22-Ig-treated rats were injected with pCAGGS-IL-22-Ig and control rats with pCAGGS-Ig using hydrodynamics-based gene delivery on day 1 or day 6. IL-22-Ig gene therapy administered on day 1 or day 6 after immunization was effective in controlling EAM as monitored by the heart weight to body weight ratio, and the myocarditis area in rats was sacrificed on day 17. Examination of the expression of IL-22-related genes in purified cells from EAM hearts suggested that IL-22-Ig acting target cells were noncardiomyocytic (NC) noninflammatory cells such as fibroblasts, smooth muscle cells, and endothelial cells. Therefore, we examined the effect of rIL-22 or serum containing IL-22-Ig on the expression of immune-relevant genes in IL-1-stimulated NC cells cultured from EAM hearts. Results showed that the expression of immunologic molecules (PGE synthase, cyclooxygenase-2, MIP-2, MCP-1, IL-6, and cytokine-induced neutrophil chemoattractant-2) in IL-1-stimulated NC cells was significantly decreased by rIL-22 or serum containing IL-22-Ig. EAM was suppressed by hydrodynamics-based delivery of plasmid DNA encoding IL-22-Ig, and the reason for this effectiveness may be that IL-22 suppressed gene expression of PG synthases, IL-6, and chemokines in activated NC noninflammatory cells.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2006) studied Experimental autoimmune myocarditis. IL-22-Ig gene therapy (pCAGGS-IL-22-Ig) vs. pCAGGS-Ig (control) was evaluated on Control of experimental autoimmune myocarditis (heart weight to body weight ratio and myocarditis area). Hydrodynamics-based delivery of IL-22-Ig gene therapy effectively suppressed experimental autoimmune myocarditis in rats by decreasing inflammatory gene expression in noncardiomyocytic cells.
Synapse has enriched 10 related papers. Consider them for comparative context: